Home Featured

Featured

Random

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

Psychedelic Bulletin #137: Oregon Approves First Psilocybin Service Centre; AMA Approves Psychedelic CPT Code; MindMed Seeks to Fend Off Proxy Contest

Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

Revive Therapeutics Acquires Unique Psilocybin Assets

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

How To Get Your Start as a Psychedelic Informed Practitioner

MEC Announces Submission of Listing Statement to the CSE in Coordination...

Q4 2025: Oregon Psilocybin Services Update

Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran...

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the...

Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its...

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

PsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement...

12 3...318 Page 1 of 318

EDITOR PICKS

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the...

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.